NCT01623661

Brief Summary

Patients with chronic kidney disease (CKD) have a defect in the tubular reabsorption of sodium, and therefore the ability to excrete a sodium load is diminished compared to healthy subjects. Urinary biomarkers reflects the water- and sodium-channel activity in the kidney and may be measured after an infusion with hypertonic saline in CKD patients and healthy subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
47

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2011

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

June 18, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 20, 2012

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2013

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

March 4, 2014

Status Verified

March 1, 2014

Enrollment Period

1.3 years

First QC Date

June 18, 2012

Last Update Submit

March 3, 2014

Conditions

Keywords

Nephrologychronic kidney diseasesodium-channelswater-channelsBCM

Outcome Measures

Primary Outcomes (1)

  • urinary biomarkers

    Urinary epithelial sodium channels (ENaC), Sodium-potassium-2chloride transporters (NKCC) and aquaporin2 channels (AQP2) before, during and after fluid infusion

    one day

Secondary Outcomes (2)

  • vaso active hormones

    one day

  • extra-and intracellular volume

    6 hours

Study Arms (1)

hypertonic saline

OTHER

hypertonic saline 3.0% (7 ml/kg)

Other: hypertonic saline

Interventions

hypertonic saline 3.0 % (7 ml/kg)

Also known as: hypertonic NaCl
hypertonic saline

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • healthy subjects
  • healthy males and females
  • age 18-70
  • BMI range 18,5-30,0 kg/m2
  • Patients with CKD
  • age 18-70
  • eGFR 15-60 ml/min
  • BMI range 18.5 - 30.0 kg/m2

You may not qualify if:

  • healthy subjects
  • hypertension (ie ambulatory BP \>130 mmHg systolic or/and \>80 mmHg diastolic)
  • history or clinical significant signs of heart, lung, liver, kidney, endocrine, brain or neoplastic disease.
  • alcohol abuse
  • drug abuse
  • smoking
  • pregnancy or nursing
  • blood donation within a month prior to examination
  • Medical treatment apart from oral contraception
  • Patients with chronic kidney disease
  • clinical significant signs of heart, lung, liver, endocrine, brain or neoplastic disease.
  • diabetes
  • immunosuppressive medications
  • smoking
  • alcohol abuse
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical Research

Holstebro, 7500, Denmark

Location

Related Publications (1)

  • Jensen JM, Mose FH, Kulik AE, Bech JN, Fenton RA, Pedersen EB. Abnormal urinary excretion of NKCC2 and AQP2 in response to hypertonic saline in chronic kidney disease: an intervention study in patients with chronic kidney disease and healthy controls. BMC Nephrol. 2014 Jun 26;15:101. doi: 10.1186/1471-2369-15-101.

MeSH Terms

Conditions

Kidney DiseasesRenal Insufficiency, Chronic

Interventions

Saline Solution, Hypertonic

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesRenal InsufficiencyChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Hypertonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Erling B Pedersen, DMSc

    Regional Hospital Holstebro

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
DMSc

Study Record Dates

First Submitted

June 18, 2012

First Posted

June 20, 2012

Study Start

December 1, 2011

Primary Completion

April 1, 2013

Study Completion

June 1, 2013

Last Updated

March 4, 2014

Record last verified: 2014-03

Locations